Engine Biosciences bags $27M Series A extension to advance precision medicine platform in oncology
Engine Biosciences has raised $27 million in a Series A extension with an eye to advance its discovery-stage precision oncology programs, which leverage both machine learning and CRISPR screening technology.
The extension raise was led by Polaris Partners with support from existing investors ClavystBio, Invus and EDBI, as well as new backers Coronet Ventures and SEEDS Capital. It brings the total funds raised by the trans-Pacific biotech since inception to $86 million, including $70 million in total Series A proceeds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.